Inetetamab Combined With Paclitaxel With/Without Pertuzumab for Previously Treated HER2-positive Advanced Breast Cancer
This study is designed to comprehensively evaluate the HER2 positive recurrent/metastatic breast cancer patients in the real world who receive the combination of Inetetamab and Paclitaxel ± Pertuzumab, including basic characteristics, efficacy and safety. The results of this study are helpful to further understand the efficacy and safety of HER2 positive patients with recurrent/metastatic breast cancer who receive the combination of Inetetamab and Paclitaxel ± Pertuzumab in the first line, and help clinical decision-making.
Breast Cancer Stage IV
DRUG: Inetetamab and Paclitaxel ± Pertuzumab
PFS, PFS is defined as the time from the participant's first dose of study treatment to the first date of either disease progression or death, whichever occurs first., Until progression, assessed up to approximately 24 months
Objective Response Rate (ORR), ORR defined as the percentage of participants with a confirmed complete response (CR) or partial response (PR) based on Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1., Until progression, assessed up to approximately 24 months|Clinical Benefit Rate (CBR), Clinical benefit rate was defined as the percentage of participants with confirmed best overall response of complete response (CR) or partial response (PR) or stable disease（SD）\>6 months determined by investigator using RECIST v1.1 on two consecutive occasions ≥4 weeks apart., Until progression or death, assessed up to approximately 24 months|Overall Survival (OS), OS is defined as the time from the participant's first dose of study treatment to the date of death., Up to approximately 3 years|Number of Participants With Adverse Events (AEs), Assessment of the toxicity profile of regimen according to the National Cancer Institute Common Toxicity Criteria version 5.0 (NCI CTCAE v 5.0)., Up to approximately 3 years
This study is designed to comprehensively evaluate the HER2 positive recurrent/metastatic breast cancer patients in the real world who receive the combination of Inetetamab and Paclitaxel ± Pertuzumab, including basic characteristics, efficacy and safety. The results of this study are helpful to further understand the efficacy and safety of HER2 positive patients with recurrent/metastatic breast cancer who receive the combination of Inetetamab and Paclitaxel ± Pertuzumab in the first line, and help clinical decision-making.